A patient started on Abilify (aripiprazole) 5 mg is experiencing restlessness and an urge to keep moving; what should be done?

Akathisia from Aripiprazole: Immediate Management Required

This patient is experiencing akathisia—a common and distressing extrapyramidal side effect of aripiprazole that requires prompt intervention to prevent medication discontinuation and worsening quality of life.

What You're Seeing

The restlessness and urge to keep moving described is classic akathisia, defined as "a sense of severe restlessness frequently manifest as pacing or physical agitation" 1. This is one of the most commonly reported side effects of aripiprazole, particularly at treatment initiation 2, and notably can occur even at low introductory doses like 5 mg 3.

Importantly, akathisia is often misinterpreted as psychotic agitation or anxiety and is a common reason for medication noncompliance 1. The FDA drug label specifically warns patients and caregivers to watch for "akathisia (psychomotor restlessness)" as it may indicate a need for close monitoring and medication changes 4.

Immediate Management Algorithm

Step 1: Confirm the Diagnosis

• Distinguish akathisia from anxiety, agitation, or worsening psychiatric symptoms
• Look for both subjective inner restlessness AND objective motor manifestations (pacing, inability to sit still)
• Timing: Symptoms typically appear within the first few days to weeks of starting antipsychotic therapy 5

Step 2: First-Line Intervention - Dose Reduction

If clinically feasible, lowering the aripiprazole dose should be attempted first 1. This is the most direct approach since:

• Akathisia is often dose-dependent 2
• Many patients develop tolerance over time 2
• Symptoms frequently resolve completely upon dose reduction or discontinuation 3, 6

Consider reducing from 5 mg to 2.5 mg daily or switching to alternate-day dosing initially.

Step 3: If Dose Reduction Insufficient - Add Symptomatic Treatment

When dose reduction alone doesn't resolve symptoms or isn't clinically appropriate:

β-blockers (e.g., propranolol) or benzodiazepines have been reported to provide relief 1. Note that antiparkinsonian agents are NOT consistently helpful for akathisia specifically 1, unlike other extrapyramidal symptoms.

Step 4: Consider Medication Switch

If akathisia persists despite dose reduction and adjunctive treatment, discontinue aripiprazole and switch to an alternative agent with lower akathisia risk. The evidence shows complete resolution of severe akathisia upon discontinuation in multiple cases 3.

Critical Context About Aripiprazole

While aripiprazole is classified as having minimal extrapyramidal side effects compared to first-generation antipsychotics 5, 7, the reality is more nuanced:

• Extrapyramidal symptoms occurred in up to 28% of aripiprazole recipients in clinical trials 8
• Compared to placebo, aripiprazole causes significantly more movement disorders as measured on standardized scales (Simpson Angus Scale, Barnes Akathisia Scale) and more patients require anticholinergic medication (RR 3.28,95% CI 1.82-5.91) 6
• Akathisia specifically is among the most commonly reported side effects alongside somnolence and nausea 2

Common Pitfalls to Avoid

1. Don't mistake akathisia for worsening psychiatric symptoms and increase the dose—this will worsen the problem 1

2. Don't automatically prescribe anticholinergics (benztropine, trihexyphenidyl)—these work for dystonia and parkinsonism but are "not consistently helpful" for akathisia 1

3. Don't ignore the patient's distress—akathisia is subjectively very uncomfortable and a major driver of medication discontinuation 1

4. Don't assume it will resolve with time alone—while some patients develop tolerance 2, many require active intervention

Documentation and Monitoring

• Document baseline abnormal movements before starting antipsychotics when possible 1
• Use standardized scales like the Barnes Akathisia Scale for objective monitoring
• Reassess need for continued treatment and lowest effective dose regularly 1

The evidence is clear: prompt recognition and intervention for aripiprazole-induced akathisia is essential to maintain treatment adherence and patient quality of life. Dose reduction is the first-line approach, with β-blockers or benzodiazepines as adjuncts if needed, and medication discontinuation if symptoms persist.